The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Official Title: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Study ID: NCT03733249
Brief Summary: This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
Detailed Description: Subjects enrolled on the BP-004 study who have completed or discontinued from the study, and are beyond Day 180 will be requested to enroll on this long-term follow up protocol. Long term follow up for gene therapy clinical and safety endpoints will continue up to 15 years.
Minimum Age: 1 Month
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
IRCCS Ospedale Pediatrico Bambino Gesù, Rome, , Italy
Name: Bellicum Pharmaceuticals
Affiliation: Bellicum Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR